Not medical advice. This site is general information only. In an emergency call your local emergency number. For advice about your own health, speak to a doctor, pharmacist or other qualified health professional.
HYVET
About the Trial
The Hypertension in the Very Elderly Trial randomized 3,845 patients aged 80 and over with systolic pressure over 160 to indapamide plus perindopril or placebo. Treatment reduced stroke by 30 percent, of borderline significance, cardiovascular events by 34 percent, and death from any cause by 21 percent. The trial stopped early on ethics: placebo patients were dying more. Before HYVET, doctors hesitated to treat the very old, fearing falls and side effects. The trial showed cautious treatment extends life in the fastest growing demographic. Its target of 150 over 80 has been widely cited for very elderly patients, though recommended targets differ between guidelines.
Related Trials
DCCT
The Diabetes Control and Complications Trial randomized 1,441 type 1 diabetes patients to intensive versus conventional insulin th...
UKPDS
The UK Prospective Diabetes Study followed over 5,000 newly diagnosed type 2 diabetes patients for a median of 10 years. Intensive...
ACCORD
The Action to Control Cardiovascular Risk in Diabetes trial tested intensive glucose control targeting HbA1c under 6.0 percent in ...
ADVANCE
ADVANCE randomized 11,140 type 2 diabetes patients to intensive gliclazide based glucose control or standard therapy. Intensive co...